Could CAR t cells tame vasculitis? early trial aims to find out
NCT ID NCT07388277
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new treatment called CC-97540, a type of CAR T cell therapy, in 12 people with severe ANCA-associated vasculitis that has not responded to standard treatments. The therapy is designed to target and destroy certain immune cells that drive the disease. The main goal is to see if it is safe and whether it can help patients achieve remission without needing other immunosuppressive drugs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CC-97540 (a type of CAR T cell therapy that targets CD19 on immune cells)
- What this could lead to
- If successful, this could offer a new treatment option for people with severe vasculitis, potentially allowing them to stop other immunosuppressive medications and stay in remission.
- What could go wrong
- This is a very early, small trial (12 people) focused on safety. CAR T cell therapy can cause serious side effects like cytokine release syndrome or infections. It may not work for everyone or lead to lasting remission.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.